Nasopharyngeal Carcinoma
Conditions
Keywords
Endostar, Nasopharyngeal Carcinoma, Chemoradiotherapy, Endostatin
Brief summary
Endostar Continuous Intravenous Infusion Combined With Induction Chemotherapy and Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma.
Detailed description
This study was a multicenter, prospective, randomized controlled clinical trial. A set of unified standards were used, including the clinical research program, inclusion criteria, exclusion criteria, chemoradiotherapy regimen and evaluation criteria. A total of 73 patients with pathologically confirmed locoregionally advanced nasopharyngeal carcinoma would be enrolled. Patients were randomly divided into two groups, with 48 patients in the combination group and 25 patients in the control group. The combination group was treated with Induction and Concurrent Chemoradiotherapy combined with Endostar. The control group was treated with Induction and Concurrent Chemoradiotherapy. The short term efficacy and side effects of these treatments would be evaluated. The 1-year, 3-year progression-free survival and overall survival would be analyzed. This data of this study might provide an alternative option for the treatment of Locoregionally advanced nasopharyngeal carcinoma with higher efficacy and low toxicity.
Interventions
DRUGEndostar
Endostar, 15 mg/m2, continous intravenous infusion, 3 cycles during induction chemotherapy, 4 cycles during concurrent chemoradiotherapy.
DRUGCisplatin
Cisplatin, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy; Cisplatin, 80 mg/m2, intravenous infusion, 2 cycles during concurrent chemoradiotherapy.
DRUGDocetaxel
Docetaxel, 75 mg/m2, intravenous infusion, 3 cycles during induction chemotherapy.
RADIATIONIntensity Modulated Radiation Therapy (IMRT)
IMRT: 66 Gy, 2-2.2 Gy per fraction, a total of 33 fractions
Sponsors
Jiangsu Cancer Institute & Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. Pathologically or clinically confirmed locally recurrent nasopharyngeal carcinoma; 2. No chemotherapy, immunotherapy, radiotherapy treatment history. 3. No evidence of distant metastasis 4. Eastern Cooperative Oncology Group performance score 0-1 5. Normal bone marrow function: white blood cell count \> 3.5 × 109 / L, hemoglobin \> 90 g / L and platelet count \> 100 × 109 / L. 6. Normal liver function: Alanine aminotransferase (ALT), aspartate aminotransferase (AST) \<1.5 times the upper limit of normal (ULN), and alkaline phosphatase (ALP) \< 2.5 × ULN 7. Normal renal function: creatinine clearance \> 60 ml/min. 8. The patient must be informed of the basic content of the study and sign an informed consent form.
Exclusion criteria
1. The pathological type is keratinized squamous cell carcinoma or basal squamous cell carcinoma. 2. Treatment is palliative. 3. A history of malignant tumors, except for well-treated basal cell carcinoma or squamous cell carcinoma and cervical carcinoma in situ. 4. Women during pregnancy or lactation (pregnancy tests should be considered for women of childbearing age; effective contraception should be emphasized during treatment). 5. Previous radiation therapy (except for non-melanoma skin cancer with a previous lesion outside the target area of radiotherapy). 6. Primary and cervical metastatic lesions have received chemotherapy or surgery (except for diagnostic treatment). 7. Having other serious illnesses may result in greater risk or affect the compliance of the trial. For example: kidney disease, chronic hepatitis, control of unsatisfactory diabetes (fasting blood glucose \> 1.5 × ULN), and mental illness. 8. A history of severe heart disease, including: cardiac function ≥ standard II, unstable angina, myocardial infarction, arrhythmia - antiarrhythmic drug therapy (except beta-blockers or digoxin), Uncontrollable hypertension. 9. According to the investigator's judgment, there are people with concomitant diseases that seriously endanger the safety of the patient or affect the patient's completion of the study. 10. Patients with a major bleeding tendency in the primary nasopharyngeal tumors.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival (PFS) | Approximately 36 months | Progression Free Survival is defined as the time from enrollment to the date of first documented disease progression or death from any cause |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate | 18months | Complete response (CR)+Partial response (PR) according to RECIST 1.1 |
| overall survival (OS) | Approximately 36 months | Overall survival was defined as the time from randomization to death from any cause |
| adverse event (AE) | Approximately 36 months | adverse event according to NCI-CTCAE (5.0) |
Contacts
Primary ContactXia He, M.D., Ph.D.
Backup ContactJuying Liu, M.D., Ph.D.
Outcome results
None listed